| Name | Tirzepatide monosodium salt |
| Description | Tirzepatide sodium salt (LY3298176 sodium salt) is a GIP and GLP-1 receptor agonist with neuroprotective activity and can be used to treat obesity. |
| In vitro | Under high glucose-induced conditions, treatment of SHSY5Y cells with Tirzepatide sodium salt at concentrations ranging from 0 to 0.4 μM for 7 days resulted in significant upregulation of CREB and BDNF mRNA expression. Additionally, it increased the protein levels of pAkt, MAP2, GAP43, AGBL4, GLUT4, SORBS1, and Bcl-2 while decreasing the protein level of BAX[1]. |
| In vivo | In diet-induced obese (DIO) mice, Tirzepatide sodium salt (10 nM/kg, subcutaneous injection) reduced body weight and food consumption. It decreased glucose, insulin, leptin, and C-peptide levels[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 255 mg/mL (52.73 mM)
|
| Keywords | GlucagonReceptor | Glucagon Receptor | GLP-1 |
| Inhibitors Related | Exendin-4 | Exendin-4 acetate | Semaglutide | (S, R)-LSN 3318839 | NNC 92-1687 | Liraglutide | Semaglutide Acetate | 6α-Methylprednisolone 21-hemisuccinate sodium salt | MK-0626 | Orforglipron | Tirzepatide Acetate(2023788-19-2 free base) | LSN3318839 |
| Related Compound Libraries | Peptide Compound Library |